<DOC>
	<DOCNO>NCT00777127</DOCNO>
	<brief_summary>This clinical trial serf purpose compare long-term effect treatment actinic keratosis - skin disorder - use Aldara® 5 % cream Solaraze® 3 % gel face scalp . In particular , find whether heal effect two medication skin lesion ( i.e . damage skin part ) maintain prolonged period .</brief_summary>
	<brief_title>Long-term Effects Imiquimod Diclofenac Actinic Keratoses</brief_title>
	<detailed_description />
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<mesh_term>Diclofenac</mesh_term>
	<mesh_term>Imiquimod</mesh_term>
	<criteria>Immunocompetent patient . A study treatment area must identifiable : Minimum 5 maximum 10 typical visible AKs one contiguous area 50 cm2 face scalp . The eyelid , inside nostrils ear , lip area inside vermilion border must part area . A positive histological finding AK grade I II ( see Section 7.1.1.2 ) . This determine suspicious lesion STA pathological area biopsied screening visit . This analysis do central histopathological laboratory . Willingness comply obligation study . Safety concern : History allergic reaction imiquimod , diclofenac , acetyl salicylic acid , non steroidal antiinflammatory drug ( NSAID ) , hyaluronic acid , relevant excipients . Pregnancy , breastfeed plan pregnancy study . Women child bear potential use highly effective method birth control define result low failure rate ( i.e . &lt; 1 % per year ) use consistently correctly implant , injectables , combine oral contraceptive , hormonal IUDs , tubal ligation vasectomise partner . Lack suitability study : Presence AK lesion STA clinically mark hyperkeratosis hypertrophy see cutaneous horn . Any topical AK treatment include imiquimod diclofenac , systemic AK treatment systemic retinoids , surgical AK treatment STA within last 2 month prior randomisation . Persisting AK lesion screen visit follow topical treatment imiquimod diclofenac STA . Topical treatment imiquimod diclofenac anywhere else body within last 2 month prior randomisation . Presence histologically confirm skin tumour STA : situ SCC include Bowen 's disease , invasive SCC , basal cell carcinoma , malignant tumour . Any dermatological disease condition may exacerbate treatment imiquimod diclofenac ( e.g . rosacea , psoriasis , atopic dermatitis ) . Any dermatological disease condition STA cause difficulty examination ( e.g . eczema ) . Systemic immunomodulatory treatment interferon , azathioprine , cyclosporine , retinoids , oral injectable corticosteroid , inhale nasal corticosteroid dosage &gt; 1200 µg/day beclomethasone equivalent within 4 week start study treatment . History malignant tumour high tumour burden systemic antitumour treatment ( incl . radiotherapy ) . History malignant skin tumour metastasise metastasis could expect . History severe cardiovascular , pulmonary , hepatic , renal , gastrointestinal , haematological , endocrine , metabolic , mental , neurological , disease within last two year . Mentally incapacitated patient . Present history drug alcohol abuse within last 3 year . Administrative reason : Exposure investigational product within last 3 month . Lack ability willingness give inform consent . Age 18 year . Lack willingness personal study relate data collect , archive transmit accord protocol . Anticipated nonavailability study visits/procedures . Vulnerable subject ( person keep detention ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>actinic keratosis</keyword>
	<keyword>invasive SCC</keyword>
	<keyword>situ SCC</keyword>
	<keyword>histological classification</keyword>
	<keyword>histological progression</keyword>
	<keyword>clinical clearance</keyword>
	<keyword>cryotherapy</keyword>
</DOC>